Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components

Authors

  • Bertrand Actor,

    1. Abteilung Molekulare Genetik, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Search for more papers by this author
    • B. Actor and J. Cobbers contributed equally to this work.

  • J.M.J. Ludwig Cobbers,

    1. Institut für Neuropathologie, Heinrich-Heine-Universität, Düsseldorf, Germany
    Current affiliation:
    1. Orthopädische Klinik, Heinrich-Heine-Universität, D-40225 Düsseldorf, Germany
    Search for more papers by this author
    • B. Actor and J. Cobbers contributed equally to this work.

  • Rainer Büschges,

    1. Institut für Neuropathologie, Heinrich-Heine-Universität, Düsseldorf, Germany
    Search for more papers by this author
  • Marietta Wolter,

    1. Institut für Neuropathologie, Heinrich-Heine-Universität, Düsseldorf, Germany
    Search for more papers by this author
  • Christiane B. Knobbe,

    1. Abteilung Molekulare Genetik, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    2. Institut für Neuropathologie, Heinrich-Heine-Universität, Düsseldorf, Germany
    Search for more papers by this author
  • Guido Reifenberger,

    1. Institut für Neuropathologie, Heinrich-Heine-Universität, Düsseldorf, Germany
    Search for more papers by this author
  • Ruthild G. Weber

    Corresponding author
    1. Abteilung Molekulare Genetik, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    2. Institut für Humangenetik, Ruprecht-Karls-Universität, Heidelberg, Germany
    • Institute of Human Genetics, University Hospital Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany
    Search for more papers by this author

Abstract

Gliosarcoma is a variant of glioblastoma multiforme characterized by two components displaying gliomatous or sarcomatous differentiation. We investigated 38 gliosarcomas for aberrations of tumor-suppressor genes and proto-oncogenes that are commonly altered in glioblastomas. Amplification of CDK4, MDM2, EGFR, and PDGFRA were found in 11% (4/35), 8% (3/38), 8% (3/38), and 3% (1/35) of the tumors, respectively. Nine of 38 gliosarcomas (24%) carried TP53 mutations. PTEN mutations were identified in 45% (9/20) of the investigated tumors. Twenty gliosarcomas were analyzed by comparative genomic hybridization (CGH). Chromosomal imbalances commonly detected were gains on chromosomes 7 (15/20; 75%), X (4/20; 20%), 9q, and 20q (3/20, 15% each); and losses on chromosomes 10 and 9p (7/20, 35% each), and 13q (3/20, 15%). Five different high-level amplifications were mapped to 4q12–q21 (1 case), 6p21 (1 case), 7p12 (2 cases), proximal 12q (4 cases), and 14q32 (1 case) by CGH. Southern blot and/or differential PCR analyses identified amplification of PDGFRA (4q12), CCND3 (6p21), EGFR (7p12), CDK4 (12q14) and/or MDM2 (12q14.3–q15), and AKT1 (14q32.3) in the respective tumors. Separate analysis of the gliomatous and sarcomatous components of eight gliosarcomas by CGH after microdissection and universal DNA amplification revealed that both components shared 57% of the chromosomal imbalances detected. Taken together, our data indicate that the genomic changes in gliosarcomas closely resemble those found in glioblastomas. However, the number of chromosomes involved in imbalances in gliosarcomas was significantly lower than that in glioblastomas, indicating a higher genomic stability in gliosarcomas. In addition, we provide further support for the hypothesis that the gliomatous and sarcomatous components are derived from a single precursor cell clone, which progressed into subclones with distinct morphological features during tumor evolution. According to our data, gain/amplification of genes on proximal 12q may facilitate the development of a sarcomatous phenotype. © 2002 Wiley-Liss, Inc.

Ancillary